Company news
Invex Therapeutics Ltd. (ASX:IXC) news
Invex Therapeutics Ltd. news releases on 6ix. Latest, Jun 15, 2021: Invex Receives Written Response from FDA on Type C Meeting
Press releases — page 2
Invex Receives Written Response from FDA on Type C Meeting
June 14, 2021
Invex Granted Type C Meeting with FDA
April 21, 2021
Appendix 4C - quarterly
April 12, 2021
Invex Successfully Concludes Protocol Assistance with EMA
December 22, 2020
Chairmans Address to Shareholders and Presentation
November 18, 2020
Investor Presentation
November 4, 2020
Invex Provides Development Update
October 30, 2020
Quarterly Report and Appendix 4C with appendix
August 7, 2020
Quarterly Report and Appendix 4C
July 23, 2020
Initial FDA and EMA Advice on Presendin Development
July 22, 2020
Notice of Allowance for Key US Exenatide Patent
July 20, 2020
Phase II Clinical Results and Capital Raising Presentation
May 22, 2020
Succesful $26 million Share Placement
May 22, 2020
Exenatide Meets Key Endpoints in IIH Clinical Trial
May 19, 2020
Appendix 4D and Half-year Report
February 26, 2020
Phase II Recruitment Completed
October 14, 2019
Japanese Patent Granted
October 7, 2019
Preliminary Final Report
August 27, 2019